Bristol/ImClone Erbitux BLA Timeline Depends On Merck KGaA Phase II Study
Executive Summary
ImClone's timeline for refiling its Erbitux BLA hinges on completion of Merck KGaA's Phase II study in colorectal cancer patients
You may also be interested in...
Erbitux BLA Resubmission Plan Set; Will Test Accelerated Approval Rules
Bristol and ImClone will take advantage of FDA's new accelerated approval interpretation in resubmitting the BLA for the oncology agent Erbitux
Erbitux BLA Resubmission Plan Set; Will Test Accelerated Approval Rules
Bristol and ImClone will take advantage of FDA's new accelerated approval interpretation in resubmitting the BLA for the oncology agent Erbitux
Bristol Erbitux: Colorectal Refiling Within 9 Months; Broader Package In 2004
Bristol-Myers Squibb could refile Erbitux in irinotecan-refractory colorectal cancer by July, Exec VP Donald Hayden told the Bear Stearns healthcare conference in New York City Sept. 17